Arrowhead reports top-line results in mixed hyperlipidaemia trial

Data ReadoutARO-DIMER-PANeutral

AI Analysis

Summary

Arrowhead Pharmaceuticals reported interim top-line results from a Phase I/IIa clinical trial investigating ARO-DIMER-PA for the treatment of mixed hyperlipidaemia. The article provides no details on efficacy, safety outcomes, or clinical significance.

Clinical Trial Data

Phase

Phase I/IIa

Outcome Details

interim top-line results reported

Importance:5/10

Sentiment:

0.00

Phase I/IIamixed hyperlipidaemiaARO-DIMER-PAclinical trialinterim results

Related Companies

$ARWR

Read the original article

Published by Clinical Trials Arena on September 16, 2026 8:29 AM

Read Original